Cybersecurity Evaluations Will Focus on Patient Harm

The GMP Letter
In a move that could simplify compliance for devices at risk from cyber threats, the FDA said it will evaluate risk based on the potential for patient harm rather than on clinical performance.

To View This Article:


Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $40.00